A Spotlight on Financial Crime
Stay on top of regional trends and novel criminal techniques so you can protect your business from financial crime.
Download Our Free Global Compliance ReportOn November 21, 2022, Delaware drug trafficker, Omar Morales Colon, was sentenced to 45 years in prison for conspiracy to commit money laundering, conspiracy to distribute cocaine, and multiple other drug and money laundering offenses. Described by the court as “one of the biggest drug traffickers in the history of the State of Delaware,” Colon and his wife laundered over a million dollars between 2009 and 2017 in drug proceeds through real estate purchases.
After giving his cocaine supplier $382,045 in cash in a hotel parking lot, Colon was arrested in May 2017. Following this, the Drug Enforcement Administration (DEA) discovered a secret underground bunker beneath Colon’s residence where the defendant concealed his “marijuana grow operation.”
According to evidence given at court, Colon and his wife deposited drug money into several different bank accounts before using the funds to buy cashier’s checks that funded multiple property purchases. At one of Colon’s properties, cocaine suppliers were offered a “safe garage” where they could extract cocaine from oxygen tanks. Colon also rented storage units in the names of various family members, and used them to store cash, marijuana, and a kilogram press used for processing cocaine.
The defendant’s wife, Shakira Martinez, has also been convicted of money laundering offenses. Their sentencing hearing is due to be held in February 2023.
In June 2021, the Financial Crimes Enforcement Network (FinCEN) included drug trafficking as one of its anti-money laundering and combatting the financing of terrorism (AML/CFT) national priorities. Following this, the Biden Administration sent its National Drug Control Strategy to Congress, instructing federal agencies to prioritize actions that will save lives and disrupt drug traffickers’ profits.
FinCEN reminds financial institutions of their reporting obligations under the Bank Secrecy Act (BSA) in its 2019 Advisory on Illicit Financial Schemes and Methods Related to the Trafficking of Fentanyl and Other Synthetic Opioids. Specifically, FinCEN reminds firms that they must conduct risk-based due diligence and, where necessary, implement enhanced policies, procedures, and controls reasonably designed to detect and report known or suspected money laundering activity.
When filing suspicious activity reports (SARs) to indicate a possible connection between suspicious transactions and drug trafficking, FinCEN instructs firms to provide all pertinent available information. According to the advisory, SAR reporting, in conjunction with effective implementation of due diligence requirements, has been crucial to identifying money laundering and terrorist financing.
In August 2021, DC-based think tank Global Financial Integrity (GFI) published a study that found more than $2.3 billion was laundered through US real estate between 2015 and 2020.
In December 2021, FinCEN issued an Advance Notice of Proposed Rulemaking (ANPRM) to help “enhance the transparency of the domestic real estate market nationwide and protect the US real estate market from exploitation by criminals and corrupt officials.” The ANPRM’s comment period closed in February 2022, with FinCEN receiving over 148 comments from stakeholders on its proposal.
While the final rule on real estate sector reporting requirements has yet to be published, compliance staff should ensure they are familiar with the ANPRM and the changes it recommends, including:
To stay up-to-date with global trends and domestic concerns surrounding money laundering in the US real estate sector, compliance staff should familiarize themselves with the Congressional Research Service’s (CRS) January 2022 fact sheet.
Stay on top of regional trends and novel criminal techniques so you can protect your business from financial crime.A Spotlight on Financial Crime
Originally published 01 December 2022, updated 22 August 2024
Disclaimer: This is for general information only. The information presented does not constitute legal advice. ComplyAdvantage accepts no responsibility for any information contained herein and disclaims and excludes any liability in respect of the contents or for action taken based on this information.
Copyright © 2024 IVXS UK Limited (trading as ComplyAdvantage).